A major leadership shake-up has taken place at the U.S. Food and Drug Administration after Dr. Tracy Beth Hoeg was removed from her position as acting director of the agency’s drug center. Hoeg, who had been overseeing the regulation and safety review of many prescription and over-the-counter medications, including antidepressants, COVID-19 vaccines, and RSV treatments, was replaced by Dr. Mike Davis, the agency’s deputy director. The change was revealed in an internal FDA email obtained by the Associated Press. Soon after the announcement, Hoeg confirmed her departure on social media, stating that she had been “fired” from the agency. She added that she had learned a great deal during her time at the FDA and left “with no regrets.” Her removal marks another dramatic development during a period of intense instability and leadership turnover at one of the nation’s most important public health agencies.
Hoeg’s departure comes amid broader upheaval within the FDA and the U.S. health system under President Donald Trump’s administration. Earlier in the same week, FDA Commissioner Marty Makary resigned from his position, while Dr. Vinay Prasad stepped down from his role overseeing vaccines and biotechnology after facing criticism from pharmaceutical companies, investors, patient advocates, and medical experts. At the same time, the FDA announced that Karim Mikhail, a longtime pharmaceutical executive hired during Makary’s leadership, would become acting director of the agency’s vaccine center. These rapid leadership changes have created uncertainty about the future direction of the FDA and raised concerns about political influence within the agency.
Hoeg became one of the FDA’s most controversial officials because of both her rapid rise within the agency and her outspoken views on public health issues. Before joining the government, she worked as a sports medicine physician and public health researcher. She gained national attention during the COVID-19 pandemic for criticizing mask mandates, school closures, vaccine mandates, and other restrictions introduced to control the spread of the virus. Hoeg collaborated with other physicians and researchers who challenged mainstream public health policies, including Marty Makary and Vinay Prasad, both of whom later joined the Trump administration. Through podcasts, interviews, blogs, and social media posts, Hoeg argued that public health authorities had become too rigid and dismissive of scientific debate during the pandemic.
One of the most controversial aspects of Hoeg’s public profile involved her participation in podcasts and online discussions questioning the safety of COVID-19 vaccines. She appeared on a podcast titled “Vaccine Curious,” which discussed disputed and scientifically unsupported claims that mRNA vaccines could contain harmful DNA contaminants. Public health experts strongly rejected those claims, insisting that the vaccines are safe and effective and that serious side effects remain extremely rare. Nevertheless, Hoeg’s willingness to challenge mainstream scientific views made her popular among conservative political groups and critics of pandemic-era restrictions, helping her gain support within the Trump administration.
Hoeg’s rise within the FDA was unusually rapid compared with traditional agency leadership careers. FDA center directors are normally longtime career scientists or physicians with decades of regulatory and management experience inside the agency. Hoeg, however, had no prior government service and limited management experience before joining the FDA in March of the previous year. Initially hired as a special assistant to Commissioner Marty Makary, she was quickly promoted to lead the FDA’s largest division, the Center for Drug Evaluation and Research, which oversees most medications used in the United States. Critics argued that her appointment reflected political loyalty more than regulatory expertise, while supporters claimed she brought fresh perspectives and a willingness to challenge institutional thinking.
During her time at the FDA, Hoeg led several controversial investigations related to vaccine safety and drug regulation. One major effort involved an “initial analysis” examining possible injuries and deaths associated with COVID-19 vaccines in children. According to reports, the analysis linked vaccines to ten reported pediatric deaths, though the FDA never publicly released the evidence or methodology behind the findings. The information reportedly appeared in an internal memo distributed by Vinay Prasad, but the agency did not formally announce the results or explain how they were developed. Public health officials at both the FDA and the Centers for Disease Control and Prevention have consistently maintained that severe vaccine-related side effects are extremely uncommon. Critics accused Hoeg and her allies of undermining confidence in vaccines without sufficient scientific transparency.
Hoeg also played a significant role in the Trump administration’s attempt to revise federally recommended childhood vaccination schedules. Working closely with Health Secretary Robert F. Kennedy Jr., she reportedly helped advance efforts to remove or weaken recommendations for several routine childhood vaccines, including influenza shots and hepatitis B vaccinations administered at birth. Medical organizations and pediatric experts strongly opposed the proposed changes, warning that lower vaccination rates could lead to outbreaks of preventable diseases. A federal judge in Boston temporarily blocked the policy changes after lawsuits argued that the administration failed to follow established scientific procedures. The administration has indicated it plans to appeal the ruling.
Another major controversy surrounding Hoeg involved antidepressant medications and pregnancy risks. She participated in the FDA’s review of a petition seeking stronger warning labels on antidepressants, alleging that the drugs could contribute to fetal abnormalities, autism, and other developmental disorders when used during pregnancy. Many experts criticized the claims as unsupported by strong scientific evidence and warned that exaggerated fears could discourage pregnant women from seeking necessary mental health treatment. The issue became more controversial after reports emerged that Hoeg attempted to hire the author of the petition as a senior adviser at the FDA. According to anonymous agency officials, some staff members became concerned because Hoeg had repeatedly referred to the petitioner as a friend, raising questions about conflicts of interest and professional judgment.
The broader political environment surrounding the FDA has become increasingly polarized in recent years. President Trump’s political allies, including anti-abortion activists, conservative commentators, vaccine skeptics, and vaping industry advocates, have repeatedly criticized the agency for being either too restrictive or too closely connected to pharmaceutical companies. Marty Makary’s resignation reportedly followed growing frustration among some of these groups, who felt the FDA was not moving aggressively enough to implement reforms. Meanwhile, Robert F. Kennedy Jr. has pushed for major changes across federal health agencies, arguing that they have become too influenced by corporate interests and insufficiently transparent. These efforts have generated support among some voters but alarm among scientists and medical professionals who fear that political ideology is beginning to outweigh evidence-based decision-making.
Hoeg’s firing may reflect deeper disagreements within the administration and the FDA over scientific standards, vaccine policy, drug regulation, and leadership style. Some analysts believe her removal could indicate growing discomfort about the controversies surrounding her investigations and public statements. Others view it as another example of the instability and internal conflict that have characterized the FDA during this administration. Because officials have not publicly explained why she was dismissed, the full reasons remain unclear.
The situation highlights the growing tension between politics and public health in the United States. Agencies such as the FDA, which were once largely insulated from partisan battles, are increasingly becoming arenas for ideological conflict over vaccines, drug safety, reproductive health, and scientific authority. Critics worry that repeated political interventions and rapid leadership changes could weaken public trust in health institutions and undermine confidence in scientific decision-making. Supporters of the administration argue that reforms are necessary to challenge bureaucratic thinking and encourage open scientific debate. As the FDA moves forward under new leadership, debates over vaccines, medicines, and public health policy are likely to remain highly controversial and politically charged.
